Will Colón

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Sorry, we do not have enough data to show an influence graph for this author.
Learn More
The approval of Provenge (Dendreon) in 2010 signaled the dawn of a new era in the development of active immunotherapeutics. For cancer treatment, the approval of Provenge® demonstrates that the immune system can effectively be harnessed to combat cancer. The outlook for active immunotherapies looks bright in terms of promising new approaches and candidates,(More)
  • 1